These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38932589)

  • 1. Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.
    Lassen MCH; Ostrominski JW; Claggett BL; Packer M; Zile M; Desai AS; Shah AM; Cikes M; Merkely B; Gori M; Wang X; Hegde SM; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
    Eur J Heart Fail; 2024 Aug; 26(8):1762-1774. PubMed ID: 38932589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the PARAGON-HF Study Results Using Win Ratio.
    Yoon M; Kim W; Kook W; Park JJ; Greenberg B
    Circ Heart Fail; 2024 Sep; 17(9):e011860. PubMed ID: 39193709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
    Chatur S; Neuen BL; Claggett BL; Beldhuis IE; Mc Causland FR; Desai AS; Rouleau JL; Zile MR; Lefkowitz MP; Packer M; McMurray JJV; Solomon SD; Vaduganathan M
    J Am Coll Cardiol; 2024 Jun; 83(22):2148-2159. PubMed ID: 38588927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
    Vaduganathan M; Mentz RJ; Claggett BL; Miao ZM; Kulac IJ; Ward JH; Hernandez AF; Morrow DA; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Lefkowitz M; McMurray JJV; Braunwald E; Solomon SD
    Eur Heart J; 2023 Aug; 44(31):2982-2993. PubMed ID: 37210743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m
    Chatur S; Beldhuis IE; Claggett BL; McCausland FR; Neuen BL; Desai AS; Rouleau JL; Zile MR; Packer M; Pfeffer MA; Lefkowitz MP; McMurray JJV; Solomon SD; Vaduganathan M
    JACC Heart Fail; 2024 Oct; 12(10):1692-1703. PubMed ID: 38842957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
    Vaduganathan M; Claggett BL; Desai AS; Anker SD; Perrone SV; Janssens S; Milicic D; Arango JL; Packer M; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2020 Jan; 75(3):245-254. PubMed ID: 31726194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
    Peikert A; Vaduganathan M; Mc Causland F; Claggett BL; Chatur S; Packer M; Pfeffer MA; Zannad F; Lefkowitz MP; Pieske B; Düngen HD; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2022 May; 24(5):794-803. PubMed ID: 35119183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial.
    Chatur S; Vaduganathan M; Peikert A; Claggett BL; McCausland FR; Skali H; Pfeffer MA; Beldhuis IE; Kober L; Seferovic P; Lefkowitz M; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2022 Oct; 24(10):1906-1914. PubMed ID: 35895867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.
    Dewan P; Shen L; Pedro Ferreira J; Jhund PS; Anand IS; Chandra A; Chiang LM; Claggett B; Desai AS; Gong J; Lam CSP; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Solomon SD; McMurray JJV
    Circulation; 2024 Jul; 150(4):272-282. PubMed ID: 38841854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
    Chatur S; Claggett BL; McCausland FR; Rouleau J; Zile MR; Packer M; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
    J Am Coll Cardiol; 2023 Apr; 81(15):1443-1455. PubMed ID: 36812948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial.
    Desai AS; Vaduganathan M; Cleland JG; Claggett BL; Barkoudah E; Finn P; McCausland FR; Yilmaz MB; Lefkowitz M; Shi V; Pfeffer MA; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Dec; 14(12):e008597. PubMed ID: 34807713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HF.
    Matsumoto S; Yang M; Shen L; Henderson A; Claggett BL; Desai AS; Lefkowitz M; Rouleau JL; Vardeny O; Zile MR; Jhund PS; Vaduganathan M; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2024 May; 26(5):1125-1138. PubMed ID: 38587090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
    Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial.
    Ostrominski JW; Claggett BL; Packer M; Pfeffer MA; Lam CSP; Zile MR; Desai AS; Jhund PS; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
    J Card Fail; 2023 Nov; 29(11):1494-1503. PubMed ID: 37220823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
    Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    McMurray JJV; Jackson AM; Lam CSP; Redfield MM; Anand IS; Ge J; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Rizkala AR; Sabarwal SV; Shah AM; Shah SJ; Shi VC; van Veldhuisen DJ; Zannad F; Zile MR; Cikes M; Goncalvesova E; Katova T; Kosztin A; Lelonek M; Sweitzer N; Vardeny O; Claggett B; Jhund PS; Solomon SD
    Circulation; 2020 Feb; 141(5):338-351. PubMed ID: 31736337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.